Try our Advanced Search for more refined results

Merck Sharp & Dohme, LLC v. Mylan Pharmaceuticals Inc. et al

  1. September 22, 2022

    Merck Gets Win In Patent Suit Over Diabetes Drugs

    A West Virginia federal judge has found that Mylan Pharmaceuticals Inc.'s planned generics of a pair of multibillion-dollar-selling diabetes drugs sold by Merck & Co. Inc. would infringe Merck's patents on the products.

  2. December 09, 2021

    IP Forecast: Amazon To Fight Damages Theory In Patent Row

    A Texas federal judge next week will hear Amazon's objection to two patent companies' damages theory that the tech giant would have paid as much as $30 million to license their patents covering technology for accessing data on a computer network. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.

  3. May 02, 2019

    Merck Sues To Nix Mylan's Plans For Diabetes Generic

    Merck & Co. Inc. filed a lawsuit on Thursday in West Virginia federal court seeking to block competing drug maker Mylan NV from moving ahead with plans to sell generic versions of two diabetes drugs that Merck says would infringe patents it owns.